Objectives: Use of Biologics to treat and prevent recurrence of scarring alopecia and alopecia areata. Identify the anti inflammatory properties in adipose stem cells, PRP, and bone marrow. Avoid costly, marginally effective, and risky medications such as prolonged steroid use and JAK inhibitors

Objectives: This presentation explores exosome therapy for scarring alopecia, a condition marked by irreversible follicular destruction due to fibrosis, trauma, or inflammation. A brief review of a 300-subject study on exosome therapy for androgenic alopecia establishes its role in follicular regeneration and scalp homeostasis. We then examine case studies using the same protocol, assessing whether exosome-driven signaling, immunomodulation, and extracellular matrix remodeling can promote follicular neogenesis in cicatricial alopecia, defining the therapeutic limits of exosome-based interventions.

Objectives: To provide a comprehensive management approach for AA patients receiving JAK inhibitors, focusing on patient selection, monitoring, adverse effect management, and long-term care.

Introduction: Jak inhibitors have revolutionized the treatment landscape for alopecia areata (AA), offering significant hair regrowth in many patients. However, optimizing patient management during JAK inhibitor therapy is crucial to maximize efficacy while minimizing risks.

Materials / method: This review synthesizes current guidelines, clinical trial data, and expert consensus on JAK inhibitor use in AA. It emphasizes patient evaluation, treatment initiation, monitoring protocols, and strategies for addressing side effects

Results: Real candidates for JAK inhibitor therapy are patients with moderate-to-severe AA who have not responded to conventional treatments. Prior to initiation, patients should undergo thorough screening for infections, malignancies, and other contraindications. Regular monitoring includes complete blood counts, liver function tests, and lipid profiles every 4–8 weeks. Adverse effects such as infections, lipid abnormalities, and rare hematologic events require prompt management, including dose adjustments or temporary treatment cessation. Long-term management involves assessing sustained response.

Conclusion: JAK inhibitors represent a significant advancement in AA treatment, but require careful patient selection, vigilant monitoring, and proactive management of adverse effects. Adherence to structured protocols ensures optimal outcomes and safety for AA patients undergoing JAK inhibitor therapy.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability